SARS-CoV-2 Saliva Test

The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus. Developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL) and as of April 16, 2020, only available in the state of New Jersey. Public expansion is expected to begin in May 2020.

Notify me on updates of this product 

Availability: Commercially Available

Professor Andrew Brooks
Chief Operating Officer and Director of Technology Development at RUCDR Infinite Biologics, Rutgers
+1 848 445 4636
57 US Highway 1
New Brunswick, NJ 08901-8554
USA
www.rutgers.edu
Manufacturer
Rutgers University
Product Name
SARS-CoV-2 Saliva Test
Detection Category
Biological
Detection Principle
Molecular;
Detection Method
Assays;
Application
Diagnostics;
Equipment Type
Diagnostic
Product Synopsis
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus. Developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL) and as of April 16, 2020, only available in the state of New Jersey. Public expansion is expected to begin in May 2020.
Availability
Commercially Available
Technology Readiness Level (TRL)
8
Market Entry Date
April 2020
User Feedback Sources
Indifferent/No user feedback
No Information Is Available
Transportability
Pocket Size
Other Biological Targets
SARS-CoV-2
Sample Introduction
Liquid; Biological sample
Training Required
<1 day training
Please enter contact info.
Email Address: 
Company: 
Name: 
Title: